

# Roslyn Stella Thelingwani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1627279/publications.pdf>

Version: 2024-02-01

13  
papers

152  
citations

1478505

6  
h-index

1199594

12  
g-index

14  
all docs

14  
docs citations

14  
times ranked

278  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinically relevant enantiomer specific <i>in vitro</i> and <i>in vivo</i> praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00769.	2.4	5
2	Evaluation of 1 $\beta$ -Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug-Drug Interaction in Healthy Volunteers. <i>Journal of Personalized Medicine</i> , 2021, 11, 457.	2.5	2
3	<i>In vitro</i> and <i>in vivo</i> human metabolism and pharmacokinetics of <i>in vitro</i> and <i>in vivo</i> praziquantel. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00618.	2.4	12
4	The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1077-1087.	1.9	14
5	Community burden of undiagnosed HIV infection among adolescents in Zimbabwe following primary healthcare-based provider-initiated HIV testing and counselling: A cross-sectional survey. <i>PLoS Medicine</i> , 2017, 14, e1002360.	8.4	33
6	Characterisation of artemisinin-chloroquinoline hybrids for potential metabolic liabilities. <i>Xenobiotica</i> , 2016, 46, 234-240.	1.1	3
7	<i>In vitro</i> screening of NIPRD-AH1 on CYP3A4 activity for plausible herb-drug interaction. <i>International Journal of Biological and Chemical Sciences</i> , 2015, 8, 2320.	0.2	0
8	Effect of NIPRISAN <sup>®</sup> on CYP3A4 activity <i>in vitro</i> . <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2015, 40, 115-118.	1.6	5
9	Evaluation of Herbal Medicines: Value Addition to Traditional Medicines Through Metabolism, Pharmacokinetic and Safety Studies. <i>Current Drug Metabolism</i> , 2015, 15, 942-952.	1.2	16
10	The effect of the Pheroid delivery system on their <i>in vitro</i> metabolism and <i>in vivo</i> pharmacokinetics of artemisone. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 313-325.	3.3	5
11	Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1313-1324.	3.3	5
12	Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from <i>P. fruticosa</i> . <i>Xenobiotica</i> , 2012, 42, 989-1000.	1.1	20
13	<i>In Vitro</i> and <i>In Silico</i> Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1286-1294.	3.3	29